Sharescart Research Club logo ×
Screener Research Unlisted Startup Funding New IPO New

  • Home
  • /
  • Sms Pharmaceuticals
Join Channel
Consolidated Standalone

SMS Pharmaceuticals

₹205 3 | 1.5%

Market Cap ₹1735 Cr.

Stock P/E 44.8

P/B 3.5

Current Price ₹205

Book Value ₹ 58

Face Value 1

52W High ₹219.3

Dividend Yield 0.15%

52W Low ₹ 75.1

Edit Ratio

SMS Pharmaceuticals Research see more...

Overview Inc. Year: 1987Industry: Pharmaceuticals & Drugs

SMS Pharmaceuticals Ltd is engaged within the production and sale of active pharmaceutical components (APIs) and their intermediates. The Company's fundamental products/offerings encompass pharmaceuticals. It's product range includes API and their intermediates. The Company gives a number of anti-ulcer, anti-fungal, anti-migraine, anti-hypertensive and different API products, which encompass Famotidine USP/Ph.Eur/JP, Lanoconazole USP/JP, Sumatriptan Base USP, Imidapril Hcl and Ondansetron Hcl USP/Ph.Eur. The Company additionally gives various erectile dysfunction, anti-cancers, anti-viral and pulmonary arterial hypertension intermediate merchandise, which encompass Ranitidine, Famotidine, Rizatriptan, Eletriptan HBr, Imidapril, Perindopril, Sildenafil citrate, Tadalafil, Imatinib and Lopinavir. The Company's plants are located in Andhra Pradesh and Telangana in India.

Read More..

SMS Pharmaceuticals Share Price

New

₹ | |

Volume
Price

Quarterly Price

Quarterly Monthly
Show Value Show %

Peer Comparison

SMS Pharmaceuticals Quarterly Results

#(Fig in Cr.) Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
Net Sales 175 121 61 64 159 149 149 135 167 161
Other Income 1 2 0 1 1 2 1 1 1 1
Total Income 176 123 61 65 160 151 151 136 167 163
Total Expenditure 128 94 65 65 146 130 126 109 139 132
Operating Profit 48 29 -4 -0 14 21 24 27 29 30
Interest 5 5 4 5 5 6 6 6 6 6
Depreciation 8 8 8 8 8 8 8 8 8 8
Exceptional Income / Expenses 0 0 0 0 0 0 0 0 0 0
Profit Before Tax 35 16 -16 -13 1 7 11 13 15 17
Provision for Tax 10 6 -25 -3 0 1 3 4 3 4
Profit After Tax 25 10 9 -10 1 5 8 9 12 12
Adjustments -2 -1 -3 -3 -3 -2 -2 1 -0 -1
Profit After Adjustments 23 9 6 -13 -2 4 6 9 12 11
Adjusted Earnings Per Share 2.7 1.1 0.7 -1.5 -0.2 0.4 0.7 1.1 1.4 1.4

SMS Pharmaceuticals Profit & Loss

#(Fig in Cr.) Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 TTM
Net Sales 612 445 465 465 412 563 520 522 612
Other Income 4 1 2 3 5 3 5 5 4
Total Income 615 447 467 468 417 567 525 527 617
Total Expenditure 522 370 372 375 332 442 405 467 506
Operating Profit 93 77 96 94 85 125 120 59 110
Interest 17 16 15 12 12 11 19 22 24
Depreciation 19 19 20 19 22 22 32 32 32
Exceptional Income / Expenses 0 0 0 0 0 0 0 0 0
Profit Before Tax 56 42 60 62 51 91 68 5 56
Provision for Tax 15 6 20 21 18 30 1 1 14
Profit After Tax 42 36 40 41 33 61 68 4 41
Adjustments -1 -7 -9 -1 -1 2 -6 -11 -2
Profit After Adjustments 41 28 32 40 32 63 62 -7 38
Adjusted Earnings Per Share 4.8 3.4 3.8 4.7 3.7 7.4 7.4 -0.8 4.6

Growth Rates

# 1 Year 3 Year 5 Year 10 Year
Sales CAGR 0% 8% 2% 0%
Operating Profit CAGR -51% -11% -9% 0%
PAT CAGR -94% -51% -37% 0%
# 1 Year 3 Year 5 Year 10 Year
Share Price CAGR 140% 9% 30% 22%
ROE Average 1% 11% 11% 13%
ROCE Average 4% 11% 13% 14%

SMS Pharmaceuticals Balance Sheet

#(Fig in Cr.) Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Shareholder's Funds 294 255 284 322 348 411 470 461
Minority's Interest 0 0 0 0 0 0 0 0
Borrowings 113 74 71 62 68 147 150 121
Other Non-Current Liabilities 48 17 25 32 46 59 43 43
Total Current Liabilities 200 156 134 156 154 211 211 255
Total Liabilities 656 502 515 572 617 828 875 880
Fixed Assets 370 290 279 281 280 457 438 412
Other Non-Current Assets 38 45 55 70 109 46 44 57
Total Current Assets 248 166 181 221 228 325 392 411
Total Assets 656 502 515 572 617 828 875 880

SMS Pharmaceuticals Cash Flow

#(Fig in Cr.) Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Opening Cash & Cash Equivalents 2 11 12 13 15 10 40 47
Cash Flow from Operating Activities 61 73 32 50 40 90 45 22
Cash Flow from Investing Activities -97 -39 -17 -35 -43 -152 -27 -30
Cash Flow from Financing Activities 44 -33 -15 -13 -2 92 -12 -32
Net Cash Inflow / Outflow 9 1 0 2 -5 31 6 -39
Closing Cash & Cash Equivalent 11 12 13 15 10 40 47 7

SMS Pharmaceuticals Ratios

# Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Earnings Per Share (Rs) 4.83 3.37 3.75 4.73 3.73 7.39 7.35 -0.83
CEPS(Rs) 7.21 6.47 7.13 7.17 6.47 9.83 11.82 4.25
DPS(Rs) 0.2 0.2 0.25 0.25 0.25 0.3 0.3 0.3
Book NAV/Share(Rs) 34.68 30.09 33.61 38.03 41.14 48.5 55.56 54.4
Core EBITDA Margin(%) 14.17 16.55 18.74 17.95 17.75 19.94 20.69 9.87
EBIT Margin(%) 11.65 12.64 15.22 14.79 13.99 16.84 15.83 4.94
Pre Tax Margin(%) 8.94 9.16 12.12 12.41 11.26 15 12.37 0.97
PAT Margin (%) 6.61 7.84 8.12 8.25 7.25 10.04 12.25 0.7
Cash Profit Margin (%) 9.7 12.07 12.12 12.09 12.14 13.7 18.06 6.52
ROA(%) 8.46 6.15 7.95 7.62 5.5 8.44 7.97 0.44
ROE(%) 17.57 12.99 15 13.67 9.76 16.07 15.41 0.83
ROCE(%) 19.54 12.73 18.17 16.57 13.06 17.62 12.6 3.79
Receivable days 35.09 33.12 16.66 18.23 30.27 46.4 50.8 65.01
Inventory Days 47.02 82.47 73.28 88.61 107.49 80.21 128.12 156.71
Payable days 51.3 93.24 66.74 54.22 68.29 59.01 91.63 101.09
PER(x) 17.26 25.47 19.64 13.16 7.15 16.84 12.76 0
Price/Book(x) 2.4 2.85 2.19 1.64 0.65 2.57 1.69 1.06
Dividend Yield(%) 0.24 0.23 0.34 0.4 0.94 0.24 0.32 0.52
EV/Net Sales(x) 1.46 1.94 1.63 1.41 0.89 2.24 1.94 1.41
EV/Core EBITDA(x) 9.64 11.26 7.91 7.01 4.33 10.14 8.41 12.35
Net Sales Growth(%) 206.01 -27.15 4.36 -0 -11.39 36.71 -7.69 0.42
EBIT Growth(%) 53.19 -21.77 32.1 -2.05 -15.09 62.21 -14.31 -68.83
PAT Growth(%) 63.48 -14.47 13.59 2.47 -21.14 86.5 11.34 -94.28
EPS Growth(%) 89.7 -30.34 11.46 26.14 -21.16 98.03 -0.49 -111.35
Debt/Equity(x) 0.7 0.59 0.51 0.45 0.44 0.61 0.55 0.55
Current Ratio(x) 1.24 1.07 1.35 1.42 1.48 1.54 1.85 1.61
Quick Ratio(x) 0.67 0.47 0.55 0.54 0.64 0.89 0.67 0.73
Interest Cover(x) 4.29 3.63 4.9 6.23 5.12 9.14 4.57 1.24
Total Debt/Mcap(x) 0.29 0.21 0.23 0.27 0.68 0.24 0.33 0.52

SMS Pharmaceuticals Shareholding Pattern

# Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024
Promoter 67.29 67.29 64.17 64.17 64.17 64.29 64.32 64.32 64.32 64.67
FII 0.65 0.61 0.63 0.59 0.59 0.59 0.67 0.6 0.59 0.17
DII 0 0 0 0 0 0 0 0 0 1.98
Public 32.06 32.1 35.2 35.23 35.23 35.12 35.01 35.08 35.09 33.17
Others 0 0 0 0 0 0 0 0 0 0
Total 100 100 100 100 100 100 100 100 100 100

Pros

  • Company has reduced debt.

Cons

  • Company has a low return on equity of 11% over the last 3 years.
  • Debtor days have increased from 91.63 to 101.09days.
  • Stock is trading at 3.5 times its book value.
  • The company has delivered a poor profit growth of -36% over past five years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

SMS Pharmaceuticals News

IPO

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

You May Also Know About

Unlisted Shares Pre-IPO Shares ESOP Shares Delisted Shares

Please Login!

Click to Login
OR
Get free Account

Error!